Neogen (NEOG) investor relations material

Strategic direction

• FY26 focused on stabilization and execution discipline; FY27 is the acceleration phase, followed by FY28 market expansion, differentiation and margin improvement.

• Core growth improved from (2.9%) in Q4 FY25 to 4.3% in Q4 FY26, with positive core growth for four consecutive quarters.

• Commercial prowess, high-impact innovation and operational excellence underpin the strategy to deepen customer relationships, grow core markets and improve profitability.

• Animal and food safety addressable markets exceed $7B and grow 4%-5%; foodborne illness costs the global economy $75B annually, with outbreaks up 50% since 2015.

• FY26 revenue was $870M, with 77% from Food Safety and 23% from Animal Safety.

Commercial model and markets

• Food Safety generated ~$650M in FY26; its portfolio spans 10 platforms, 10,000+ SKUs and 100+ validated methods, with more than half of revenue outside the U.S.

• Point-of-processing testing is a growth opportunity, with $700M in testing spend expected to shift from centralized labs over five years; the on-site market adds ~$140M annually.

• Strategic accounts grew 6.2%; commercial indicators included a $142M qualified pipeline, $13M in Q1 wins and 32% more new opportunities per quarter.

• Global account teams aim to standardize solutions and expand share of wallet; customers using Neogen Analytics increased consumable use by more than 1.5x.

• Animal Safety has an international expansion runway, with ~15% of sales outside the U.S.; priorities include Europe, Latin America and Asia-Pacific.

Innovation and product development

• Innovation goals include 5+ annual product launches, $100M new-product revenue contribution, 15% targeted ROIC and a 10x vitality index by FY31.

• Petrifilm development is being internalized; its addressable market could expand more than 2.5x, including a $2B opportunity in adjacent applications by FY31.

• The new Petrifilm facility has validated equipment and tested 75,000+ plates, with capacity planned at ~3x current levels; the 17-SKU transfer will be phased to protect supply.

• R&D investment is planned to rise ~50% in FY27 and reach ~5% of revenue by FY31; licensing and co-development are additional innovation pathways.

• Hinalea collaboration advances hyperspectral imaging for food safety; exclusive application rights and a new camera priced 70% below the previous model support development.